MAP2K7 and lung cancer: In the present work, we investigated the “actionability” of these lung cancer-derived CRAF mutations with ERK pathway inhibitors (RAF and MEK inhibitors) and further determined the comparative efficacy of two classes of RAF inhibitors in targeting these mutations.